New 'Off-the-Shelf' cell therapy targets Hard-to-Treat blood cancers
NCT ID NCT07131254
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This early-phase study tests an experimental cell therapy called GT719 for adults with relapsed or refractory B-cell blood cancers (lymphoma and leukemia) that have not responded to standard treatments. The therapy uses donor-derived immune cells designed to attack cancer cells carrying a protein called CD19. The main goals are to check safety and find the right dose, with 34 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ganzhou City People's Hospital
RECRUITINGGanzhou, Jiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.